depression

R&D

At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.

News

Flow Neuroscience has secured FDA approval for FL-100, the first at-home brain stimulation device for major depressive disorder.

News

Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.

News

A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses.

News

Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.

News

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.